168 related articles for article (PubMed ID: 34009141)
1. Recent evidence on the effect of treatment of metabolic acid on the progression of kidney disease.
Hultin S; Johnson DW; Badve SV
Curr Opin Nephrol Hypertens; 2021 Sep; 30(5):467-473. PubMed ID: 34009141
[TBL] [Abstract][Full Text] [Related]
2. VALOR-CKD: A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial Evaluating Veverimer in Slowing Progression of CKD in Patients with Metabolic Acidosis.
Tangri N; Mathur VS; Bushinsky DA; Klaerner G; Li E; Parsell D; Stasiv Y; Walker M; Wesson DE; Wheeler DC; Perkovic V; Inker LA
J Am Soc Nephrol; 2024 Mar; 35(3):311-320. PubMed ID: 38261535
[TBL] [Abstract][Full Text] [Related]
3. Design and population of the VALOR-CKD study: a multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of veverimer in slowing progression of chronic kidney disease in patients with metabolic acidosis.
Mathur VS; Bushinsky DA; Inker L; Klaerner G; Li E; Parsell D; Perkovic V; Stasiv Y; Walker M; Wesson DE; Wheeler DC; Tangri N
Nephrol Dial Transplant; 2023 May; 38(6):1448-1458. PubMed ID: 36331426
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of Action of Veverimer: A Novel, Orally Administered, Nonabsorbed, Counterion-Free, Hydrochloric Acid Binder under Development for the Treatment of Metabolic Acidosis in Chronic Kidney Disease.
Klaerner G; Shao J; Biyani K; Kade M; Kierstead P; Gbur R; Tabakman S; Nguyen S; Buysse J
J Pharmacol Exp Ther; 2020 Dec; 375(3):439-450. PubMed ID: 33033169
[TBL] [Abstract][Full Text] [Related]
5. Effects of veverimer on serum bicarbonate and physical function in women with chronic kidney disease and metabolic acidosis: a subgroup analysis from a randomised, controlled trial.
Mathur VS; Wesson DE; Tangri N; Li E; Bushinsky DA
BMC Nephrol; 2022 Feb; 23(1):82. PubMed ID: 35216581
[TBL] [Abstract][Full Text] [Related]
6. A basic solution for a complex problem: does treatment of metabolic acidosis slow CKD progression?
Bodker K; Freidin N; Arora N
Curr Opin Nephrol Hypertens; 2024 May; 33(3):304-310. PubMed ID: 38420899
[TBL] [Abstract][Full Text] [Related]
7. Effects of veverimer on serum bicarbonate and physical function in diabetic patients with chronic kidney disease and metabolic acidosis: subgroup analysis from a randomized, controlled trial.
Mathur VS; Li E; Wesson DE
Nephrol Dial Transplant; 2022 Jun; 37(7):1302-1309. PubMed ID: 34240198
[TBL] [Abstract][Full Text] [Related]
8. Advances in management of chronic metabolic acidosis in chronic kidney disease.
Chen W; Abramowitz MK
Curr Opin Nephrol Hypertens; 2019 Sep; 28(5):409-416. PubMed ID: 31232712
[TBL] [Abstract][Full Text] [Related]
9. Veverimer versus placebo in patients with metabolic acidosis associated with chronic kidney disease: a multicentre, randomised, double-blind, controlled, phase 3 trial.
Wesson DE; Mathur V; Tangri N; Stasiv Y; Parsell D; Li E; Klaerner G; Bushinsky DA
Lancet; 2019 Apr; 393(10179):1417-1427. PubMed ID: 30857647
[TBL] [Abstract][Full Text] [Related]
10. Metabolic acidosis and kidney disease: does bicarbonate therapy slow the progression of CKD?
Kovesdy CP
Nephrol Dial Transplant; 2012 Aug; 27(8):3056-62. PubMed ID: 22851628
[TBL] [Abstract][Full Text] [Related]
11. Importance of Metabolic Acidosis as a Health Risk in Chronic Kidney Disease.
Vincent-Johnson A; Scialla JJ
Adv Chronic Kidney Dis; 2022 Jul; 29(4):329-336. PubMed ID: 36175070
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis and Treatment of Metabolic Acidosis in Patients with Chronic Kidney Disease - Position Statement of the Working Group of the Polish Society of Nephrology.
Adamczak M; Masajtis-Zagajewska A; Mazanowska O; Madziarska K; Stompór T; Więcek A
Kidney Blood Press Res; 2018; 43(3):959-969. PubMed ID: 29895022
[TBL] [Abstract][Full Text] [Related]
13. Current status of bicarbonate in CKD.
Dobre M; Rahman M; Hostetter TH
J Am Soc Nephrol; 2015 Mar; 26(3):515-23. PubMed ID: 25150154
[TBL] [Abstract][Full Text] [Related]
14. Does correction of metabolic acidosis slow chronic kidney disease progression?
Goraya N; Wesson DE
Curr Opin Nephrol Hypertens; 2013 Mar; 22(2):193-7. PubMed ID: 23380803
[TBL] [Abstract][Full Text] [Related]
15. Long-term safety and efficacy of veverimer in patients with metabolic acidosis in chronic kidney disease: a multicentre, randomised, blinded, placebo-controlled, 40-week extension.
Wesson DE; Mathur V; Tangri N; Stasiv Y; Parsell D; Li E; Klaerner G; Bushinsky DA
Lancet; 2019 Aug; 394(10196):396-406. PubMed ID: 31248662
[TBL] [Abstract][Full Text] [Related]
16. Correction of metabolic acidosis improves insulin resistance in chronic kidney disease.
Bellasi A; Di Micco L; Santoro D; Marzocco S; De Simone E; Cozzolino M; Di Lullo L; Guastaferro P; Di Iorio B;
BMC Nephrol; 2016 Oct; 17(1):158. PubMed ID: 27770799
[TBL] [Abstract][Full Text] [Related]
17. Metabolic Acidosis in CKD: A Review of Recent Findings.
Melamed ML; Raphael KL
Kidney Med; 2021; 3(2):267-277. PubMed ID: 33851122
[TBL] [Abstract][Full Text] [Related]
18. Metabolic acidosis is common and associates with disease progression in children with chronic kidney disease.
Harambat J; Kunzmann K; Azukaitis K; Bayazit AK; Canpolat N; Doyon A; Duzova A; Niemirska A; Sözeri B; Thurn-Valsassina D; Anarat A; Bessenay L; Candan C; Peco-Antic A; Yilmaz A; Tschumi S; Testa S; Jankauskiene A; Erdogan H; Rosales A; Alpay H; Lugani F; Arbeiter K; Mencarelli F; Kiyak A; Dönmez O; Drozdz D; Melk A; Querfeld U; Schaefer F;
Kidney Int; 2017 Dec; 92(6):1507-1514. PubMed ID: 28729033
[TBL] [Abstract][Full Text] [Related]
19. Metabolic Acidosis in CKD: Core Curriculum 2019.
Raphael KL
Am J Kidney Dis; 2019 Aug; 74(2):263-275. PubMed ID: 31036389
[TBL] [Abstract][Full Text] [Related]
20. Approach to the Treatment of Chronic Metabolic Acidosis in CKD.
Raphael KL
Am J Kidney Dis; 2016 Apr; 67(4):696-702. PubMed ID: 26776539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
